Dramatic changes to the regulatory landscape for in vitro diagnostic (IVD) medical devices are in the making. Some of the most impactful changes include a new classification of IVDs, an expansion of post market surveillance and the increased need for Notified Body review. Most medical device manufacturers are aware that failure to meet In Vitro Diagnostic Regulation (IVDR) 2017/746 deadlines can result in either failure to obtain a CE marking or loss of a currently valid CE mark. The deadlines, however, are not written in stone.
This article takes a closer look at the revised IVDR implementation timeline and potential impacts on certification. Access the article here.
The article is free!Simply fill in the form below, verify your email address |
Related Posts
- 56Next-generation sequencing (NGS) assays sequence the genes in human biological samples making them a unique subset of in vitro diagnostic devices (IVDs). Unlike other IVDs, NGS test results determine applicable patient populations, and which genetic variants can affect the authenticity of a test result. This article offers a bulleted list of clinical performance evaluators by…
- 48By Erica Kramer, Ph.D., Senior Nerac Analyst/Medical Writer Originally Published: June 30, 2020 In May 2017, the European Parliament and Council published Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), repealing Directive 98/79/EC (IVDD). The new regulation will apply starting May 26, 2022. Unlike under the IVDD, which allowed for self-certification for many…
- 42By Richard Conforti, M.S., Nerac Analyst, Originally Published: April 19, 2016 In 2014 the Chinese Food and Drug Administration, CFDA, updated their regulations on medical devices. These updates substantially changed the way in which a medical device company, particularly international companies not based or founded in China, registers their devices in China. In part 1…